Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status.
about
DHHC-7 and -21 are palmitoylacyltransferases for sex steroid receptorsCancer Hallmarks, Biomarkers and Breast Cancer Molecular SubtypesMolecular Imaging of Biomarkers in Breast CancerIdentifying and targeting tumor-initiating cells in the treatment of breast cancerCIViC databasePredictive and prognostic molecular markers for cancer medicineDecreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions.Pathways to tamoxifen resistance.Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.Inverse regulation of EGFR/HER1 and HER2-4 in normal and malignant human breast tissue.EGFR associated expression profiles vary with breast tumor subtypeEstrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatmeProtein expression profile and prevalence pattern of the molecular classes of breast cancer--a Saudi population based studyThe clinical significance of PR, ER, NF- κ B, and TNF- α in breast cancerEpidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomesRAS pathway biomarkers for breast cancer prognosis.Using image analysis as a tool for assessment of prognostic and predictive biomarkers for breast cancer: How reliable is it?EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer.A nation-wide multicenter 10-year (1999-2008) retrospective clinical study of endocrine therapy for Chinese females with breast cancer.Progesterone receptor status and Ki-67 index may predict early relapse in luminal B/HER2 negative breast cancer patients: a retrospective study.Long-term cultures of stem/progenitor cells from lobular and ductal breast carcinomas under non-adherent conditions.Stratified pathway analysis to identify gene sets associated with oral contraceptive use and breast cancer.The changing role of pathology in breast cancer diagnosis and treatment.Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancerEPMA position paper in cancer: current overview and future perspectives.Clinicopathologic Characteristics of Oestrogen Receptor-Positive/Progesterone Receptor-Negative/Her2-Negative Breast Cancer According to a Novel Definition of Negative Progesterone Receptor Status: A Large Population-Based Study from China.Ano1/TMEM16A Overexpression Is Associated with Good Prognosis in PR-Positive or HER2-Negative Breast Cancer Patients following Tamoxifen Treatment.In vivo magnetic resonance imaging of the estrogen receptor in an orthotopic model of human breast cancer.Therapeutic advances in BIG3-PHB2 inhibition targeting the crosstalk between estrogen and growth factors in breast cancerAdvantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67.Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapyPreclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer.Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer.Prognostic impact of progesterone receptor status combined with body mass index in breast cancer patients treated with adjuvant aromatase inhibitor.Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer.Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-upClinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer.Does estrogen receptor determination affect prognosis in early stage breast cancers?Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer.Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit.
P2860
Q24294755-24288ED7-AAA9-4A59-92AB-046AFA4C027CQ26743510-3CEA07BB-0427-4C91-9C16-4E048A3F3C02Q26772870-221143C9-65B9-42CA-99EB-05C5493D72CBQ26851827-77C324D3-4C20-41DD-A8A6-1EE165B03509Q27612411-B59A54B9-2AF9-40BD-9270-6A1B1F99ADE9Q28743108-0BBC8A8B-6E36-4F9E-B786-4CE7940F0235Q30439093-960D23C3-1707-4E7B-871B-2E249A0BE1BEQ30441001-FD88B13B-D925-429A-B265-038A9DC5E4E6Q31031200-231B2225-D11B-469D-9781-286C9F7F4320Q31134061-77186739-A9F7-4B0F-A332-A1515374C413Q33292502-4B2D5FC3-7AD1-4736-BE5B-BC7A159E91F2Q33561588-81E6DAA9-7AEE-4F3A-B560-6E0A2F535809Q33584351-4F031385-C0E8-4C36-86CA-97E63BA40D85Q33597991-3BDFBA43-321F-4D7B-889E-07E3222953A9Q33691211-684A5487-78E4-4C57-BEC5-1337F69BACD5Q33757299-9DCC5871-07E1-48B8-9822-5DDB8CE2C307Q33789913-205C33C8-6FA3-42F0-9A90-199B10FF47B2Q33793142-31815337-09F9-4C20-A6E8-F4763BDEFCB3Q33921197-0EA660E8-C74B-4F6C-B405-536C134AC887Q34109691-1B196259-A53F-43C1-86BC-16CF9879F413Q34491214-409C219D-BA23-4630-A08B-9B8CD44D8608Q34680457-390D051B-30EB-4D76-8EA7-B89A00379719Q35082260-44A1B9A3-E9FC-4620-A969-6ABDE2471D9EQ35527355-5B5D7CCF-AC6C-49B6-8C75-D88B947C5C1BQ35532215-42E76AF8-D75A-4B44-B350-4632A84DFD45Q35566057-CF7E6F5E-472D-4E30-ACFC-8D24B0DCCFFCQ35593599-519B40AB-5144-4266-8F68-251AEE008988Q35624196-04F0E7A2-1A4C-4A13-85A0-075D6FC2E205Q35674177-20A964D1-13CE-4C43-B4A0-A829AAB48BB9Q35889626-E1CFFB8F-04E3-4282-8F60-8ED34A07A70CQ36223407-2F827D77-8FB0-491C-95DB-4B396B8F6F5CQ36245376-1DD58AD2-8484-4A58-9B63-BB3E9EA1BB1BQ36299320-2A757AF4-A3BA-4921-9EF4-9DBE1EB4C5F5Q36334705-A372377E-9C74-4C20-BB25-2B3C40EB0B11Q36408570-F22923AC-F162-4692-8A09-FA0B44FDA2D6Q36442340-F3B538BC-446F-4F38-B0EC-C32D825F5031Q36458731-FA6394A7-6DA7-47BC-B613-0B31BDFFDB75Q36493141-E01F6019-CC76-4132-AF97-353A8C605A2DQ36494250-EFCA476F-7A6A-4DA4-93C8-C0493EF81D28Q36514782-E6CC65AB-A277-49C4-A2FB-214ACA49D239
P2860
Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Benefit from adjuvant tamoxife ...... EGF receptor and HER2 status.
@ast
Benefit from adjuvant tamoxife ...... EGF receptor and HER2 status.
@en
Benefit from adjuvant tamoxife ...... EGF receptor and HER2 status.
@nl
type
label
Benefit from adjuvant tamoxife ...... EGF receptor and HER2 status.
@ast
Benefit from adjuvant tamoxife ...... EGF receptor and HER2 status.
@en
Benefit from adjuvant tamoxife ...... EGF receptor and HER2 status.
@nl
prefLabel
Benefit from adjuvant tamoxife ...... EGF receptor and HER2 status.
@ast
Benefit from adjuvant tamoxife ...... EGF receptor and HER2 status.
@en
Benefit from adjuvant tamoxife ...... EGF receptor and HER2 status.
@nl
P2093
P3181
P356
P1433
P1476
Benefit from adjuvant tamoxife ...... EGF receptor and HER2 status.
@en
P2093
J Houghton
R Sainsbury
P304
P3181
P356
10.1093/ANNONC/MDL016
P577
2006-05-01T00:00:00Z